Acquisitions for Aptiv and Eurofins, partnering for Spaulding and fundraising at Clinipace
US contract research organisation (CRO) Aptiv Solutions has bought SRA Global Clinical Development, a division of North Carolina-based SRA International.
The deal, financial terms of which were not disclosed, will see SRA’s 100-strong clinical trial and regulatory services team and offices in the US, France and the UK join the Aptiv network.
Aptiv Solutions’ CEO, Pat Donnelly, said: “With this acquisition we continue to broaden our client base and add significant expertise and scale to Aptiv Solutions.”
Aptiv was formed earlier this year when six CROs - Averion International, Trio Clinical Research, ClinResearch, Niphix, Addplan and Fulcrum Pharma – joined to establish a CRO specialised in adaptive trial protocols.
French CRO Eurofins is also in acquisition mode. The firm signed a definitive, mutually-binding agreement on September 30 to acquire a 67 per cent stake in each of two Fondation Institut Pasteur de Lille subsidiaries, namely IPL Invest and IPL Santé Environnement Durable Nord.
The two IPL units specialise in environmental testing and generate around €45m a year in combined revenue. The deal, which is expected to complete later this month, follows just a few weeks after Eurofins expanded its food testing lab in Nantes and is a further example of its diversification efforts.
Spaulding Clinical Research, which recently partnered with Eurofins, has entered into an accord with telemonitoring group GrandCare Systems in a deal focused on Spaulding’s iQ electrocardiograph.
The agreement, finical terms of where were not provided, will see GrandCare incorporate iQ into its in home monitoring infrastructure to create, according to the firms, a telemedicine home diagnostic service.
The partnership is the third Spaulding has signed in as many months behind its deals with Eurofins and more recently, Frontage.
Finally for this round-up we look at US CRO Clinipace Worldwide. The firm has raised $15m in a series C financing round led by Morgan Stanley Expansion Capital.
Clinipace said it plans to use the money to build “therapeutic expertise” and “global capacity,” but did not go into specifics.
Previously Clinipace has expanded its global footprint and offering through acquisitions – buying PFC Pharma Focus to enter the European market in May and regulatory affairs firm Regulus Pharmaceutical Consulting in March.
